Stay updated with breaking news from 91307c10. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities research analysts expect United Therapeutics Co. (NASDAQ:UTHR – Get Rating) to report earnings of $3.81 per share for the current quarter, Zacks reports. Five analysts have made estimates for United Therapeutics’ earnings, with the lowest EPS estimate coming in at $3.42 and the highest estimate coming in at $4.35. United Therapeutics posted earnings per […]
United Therapeutics (NASDAQ:UTHR – Get Rating) posted its quarterly earnings data on Wednesday. The biotechnology company reported $5.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.65 by $1.38, MarketWatch Earnings reports. The firm had revenue of $461.90 million during the quarter, compared to analysts’ expectations of $420.02 million. United Therapeutics […]
Brokerages forecast that United Therapeutics Co. (NASDAQ:UTHR – Get Rating) will report $2.96 earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for United Therapeutics’ earnings, with estimates ranging from $2.27 to $3.33. United Therapeutics posted earnings per share of $0.61 in the same quarter last year, which […]
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 1,030,000 shares, a decline of 38.3% from the March 31st total of 1,670,000 shares. Based on an average daily volume of 444,800 shares, the short-interest ratio is […]
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $189.18, for a total value of $1,135,080.00. Following the transaction, the executive vice president now directly owns 36,397 shares of the […]